Clinical Trial Update: TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on TTI-622 in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TTI-622 (TTI-622)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING